NEW YORK, May 19, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Angiongenesis Inhibitors and Stimulators Industry
http://www.reportlinker.com/p0459142/Global-Angiongenesis-Inhibitors-and-Stimulators-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
This report analyzes the worldwide markets for Angiogenesis Inhibitors and Stimulators in US$ Million by the following product segments - Angiogenesis Inhibitors, and Angiogenesis Stimulators. Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 72 companies including many key and niche players worldwide such as Abbott Laboratories, Adnexus Therapeutics, Inc., Æterna Zentaris Inc., Amgen, Inc., Angstrom Pharmaceuticals Inc., AstraZeneca Plc, Bayer HealthCare AG, Callisto Pharmaceuticals, Inc., Celgene Corporation, Celltech Group Plc., Cephalon Inc., Eisai Inc., Eli Lilly And Company, ImClone Systems Inc., EntreMed Inc., GenVec Inc., Genzyme Corp., GlaxoSmithKline plc, Merck KGaA, Novartis, OSI Pharmaceuticals, Inc., Eyetech, Inc., Pfizer Inc., Progen Industries, Regeneron Pharmaceuticals, Roche, Genentech Inc., Chugai Pharmaceutical Co. Ltd., Silence Therapeutics, and ThromboGenics Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability And Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions And Scope Of Study 3
1. Angiogenesis Inhibitors 4
2. Angiogenesis Stimulators 4
2. MARKET OUTLOOK 5
Angiogenesis: In the Spotlight 5
Angiogenesis: A Preview 5
Analysis by Region 5
US: The Single Largest Market 5
Angiogenesis Regulating Products Market in Europe 6
Market for Angiogenesis Regulating Products in Rest of World 6
Table 1: Global Market for Angiogenesis Regulating Products
(2009-2015): Geographic Regions Ranked by CAGR - USA,
Europe, and Rest of World (includes corresponding
Graph/Chart) 6
Selective Analysis of Angiogenesis Regulating Products 6
3. MARKET OVERVIEW 7
Angiogenesis Makes Inroads 7
Angiogenesis: Ushering-In a New Era 7
Angiogenesis: Fact File 8
Milestones in Research Achieved Over the Years 9
Anti-Angiogenic Drugs Market - An Overview 10
Angiogenic Inhibitors Market to Surge 10
The Long Journey for Anti-Angiogenesis Therapies 10
Approved Anti-Angiogenesis Drugs in the Market 11
Select FDA-Approved Anti-Angiogenic Drugs/ Therapeutics In
Oncology By Type 11
Small Molecule Tyrosine Kinase Inhibitors 12
Inhibitors of mTOR 13
Other Anti-Angiogenic Agents 13
Leading Drugs in the Market 14
Avastin Leads the Fray 14
Table 2: Select Leading Drugs in the Global
Anti-Angiogenesis Market: Annual Sales in US$ Million for
Years 2008 & 2009 (includes corresponding Graph/Chart) 14
Overview of Select Leading Drugs 15
Avastin 15
Survival Benefit Conferred by Avastin 16
Mechanism of Action 17
General Mode of Delivery 17
Side Effects Elicited on Administering Avastin 17
ERBITUX™ (Cetuximab) 17
Regulatory Approvals 18
Erbitux in Head and Neck Cancer 18
Glivec/Gleevec (imatinib mesylate) 19
Herceptin (Tractuzumab) 19
Iressa (gefitinib) 19
Sutent (Sunitinib) 20
Other Regulatory Approvals 20
Sunitinib in Various Indications 20
Sunitinib in Renal Cell Carcinoma (RCC) 20
Sutent in Gastrointestinal Stromal Tumors 21
Cost Related Issues 21
Tarceva (Erlotinib) 21
Other Regulatory Approvals 22
Thalomid® (thalidomide) 22
Table 3: Thalomid - Percentage Breakdown Based on Relative
Oncology Application (includes corresponding Graph/Chart) 22
Cilengitide 23
Imiquimod 23
Angiogenesis Inhibitors - Pipeline Status 24
Select Anti-Angiogenesis Drugs in Phase III Development 24
Select Anti-Angiogenesis Drugs in Phase II Development 25
Select Anti-Angiogenesis Drugs in Phase I Development 26
Approved and Pipeline Indications of Select Anti-VEGF/VEGFR
Drugs 26
Novel Targets for Anti-Angiogenic Activity 27
Approved and Pipeline HER Receptor-Targeting Drugs 28
Select Approved and Pipeline m-TOR Inhibitors 28
Integrins 28
Select Integrin Targeting Drugs Under Development 29
Angiogenic Inhibitors - By Disease Application 29
Cancer 29
Various Types of Cancers Targeted by Angiogenesis
Inhibitors in Phase III Clinical Development 29
Diabetic Retinopathy 30
Female Reproductive Cycle 30
Psoriasis 30
Inflammatory Diseases 30
Table 4: Classification of Anti-Angiogenic Compounds Based
on Most Commonly Targeted Indication (includes
corresponding Graph/Chart) 31
Angiogenesis Inhibitors in Eye Related Diseases 31
Age-Related Macular Degeneration 31
Wet AMD 32
Dry AMD 32
Select Anti-Angiogenic Drugs Approved by FDA for Treatment
of Eye Diseases 32
Angiogenesis Inhibitors in Dermatology 33
Select Drugs/Therapeutics with Angiogenic Mode of Action
Approved by FDA for Dermatology 33
4. MARKET TRENDS 34
Cancer - The Key Target Indication for Research in Anti-
Angiogeneis Drugs 34
Avastin Continues to Record Robust Growth 34
New Markets Offer Higher Potential for Herceptin 34
Increased Use Drives Tarceva's Growth in Developed Markets 34
Angiogenesis Inhibitors Continue to Dominate RCC Drug Market 35
Votrient to Lead Renal Cell Carcinoma (RCC) Drug Market 35
Table 5: Leading Drugs in the Global Second Line Advanced
Renal Cell Carcinoma Market (2009): Percentage Breakdown by
Value Sales for Nexavar, Torisel, Afinitor, Avastin, and
Others (includes corresponding Graph/Chart) 36
Clinical Benefits of Votrient Over Sutent 36
Avastin's Approval for Breast Cancer Treatment Under Threat 37
5. ANGIOGENESIS REPERTOIRE 38
An In-depth Insight into Angiogenesis 38
Angiogenesis: At a Glance 38
Requisites for Angiogenesis 38
Endogenous Regulators of Angiogenesis 39
Angiogenic Process: Sequence of Events 39
Angiogenesis Process in Children 40
Angiogenesis Process in Adults 40
The Process of Angiogenesis in Thyroid Gland 40
6. ANGIOGENESIS INHIBITORS 41
Table 6: Global Market for Angiogenesis Inhibitors
(2009-2015): Geographic Regions Ranked by CAGR - USA, Europe,
and Rest of World (includes corresponding Graph/Chart) 41
Angiogenic Inhibitors: Basic Framework 41
Natural Inhibitors 41
Thrombospondin 41
Interferon 41
Cryptic Inhibitors 42
Other Natural Inhibitors 42
Natural Sources for Anti-Angiogenic Action 42
Potential Anti-Angiogenic Drugs of Natural Origin 42
Angiogenic Inhibitors: On the Verge of Attaining Superior
Clinical Efficacy 42
Endogenous vs Synthetic Agents 43
Angiogenesis Inhibitors: Classification Based on Source of
Origin 43
Anti-Angiogenic Molecules: Classification Based on Mode of
Action 44
Broad Overview of Anti-Angiogenic Therapies 44
Pre-Requisites for Any Drug to be an Angiogenic Inhibitor 44
Specific Therapeutic Strategies of Anti- Angiogenesis Agents 45
Inhibiting Angiogenesis In Vivo 45
Antiangiogenic Tumor Therapy 46
Antivascular Therapy: Adding a New Dimension 46
MMPs - Exhibiting Dual Role 46
Angiogenesis Inhibitors Vs Standard Chemotherapy 47
Comparison Between Cytostatic Antiangiogenesis and Cytotoxic
Chemotherapy 47
Proteoglycan Mixture: Therapeutic Powerhouse 47
Features of VascuStatin 48
Angiogenesis Inhibition Versus Cytotoxic Therapy 48
Relationship Between Copper and Angiogenesis 48
Anti-Angiogenesis Action of Pencillamine 48
Outline of Steps Involved in Drug Discovery for Angiogenesis 49
Drug Delivery: Their Influence on Therapeutics 49
7. PROMOTERS OF ANGIOGENESIS/ ANGIOGENESIS STIMULATORS 51
Angiogenesis Stimulators 51
Growth Factors 51
Angiogenic Stimulators in the Market 51
Table 7: Global Market for Angiogenesis Stimulators
(2009-2015): Geographic Regions Ranked by CAGR -USA, Europe,
and Rest of World (includes corresponding Graph/Chart) 51
Stimulators Exhibiting Profound Influence on Angiogenesis 51
Vascular Endothelial Growth Factor (VEGF) 51
VEGF and Their Influence on Diabetes and Diabetic Retinopathy 52
Fibroblast Growth Factors (FGFs) 52
Basic Fibroblast Growth Factor (bFGF) 52
Placental Growth Factor (PlGF) 52
Recombinant a4 Fragment 53
Hepatocyte Growth Factor/ Scatter Factor (HGF/SF) 53
Angiogenin 53
Platelet Derived Endothelial Cell Growth Factor 53
Applications of Angiogenic Stimulators vis-à-vis Disease
Perspective 53
Cardiac Diseases 53
Wound Healing and Burns 54
Critical Limb Ischaemia 54
Status of Angiogenic Inducers 54
Angiogenic Therapies for Tissue Repair & Regeneration 54
Select Devices Supporting Therapeutic Angiogenesis 55
Angiogenesis in Ischemic Heart 55
Factors Influencing Ischemic Angiogenesis 55
Angiogenesis and CAD 55
Angiogenesis in Wound Healing 56
Factors Stimulating Wound Angiogenesis 56
Factors Impairing Wound Angiogenesis 56
Angiogenic Therapy Vs Conventional Therapy 57
Types of Angiogensesis 57
Excessive Angiogenesis 57
Insufficient Angiogenesis 57
Tumor Angiogenesis 57
Sequence of Actions 57
Angiogenesis and Tumor Progression 58
Oncogenes vis-à-vis Potential Pro-angiogenic Activities on
Tumor Angiogenesis 58
Role of Angiogenesis in Skin Diseases 58
Current State of Select Drugs & Their Targeted Application 59
Analysis of Developmental Activities Between Decades 59
Role of Enzymes and Inflammatory Cells in Angiogenesis 60
Angiogenic Imbalance Augments Retinal Neovascularization 60
Oncogenes & VE -cadherin - A Facilitating Role 60
8. PRODUCT APPROVALS AND LAUNCHES 61
Pfizer Obtains European Approval for SUTENT® to Treat
Pancreatic NET 61
Novartis Obtains FDA Approval of New Indication for Afinitor 61
FDA Approves Herceptin for Treating Metastatic Adenocarcinoma 61
Roche Introduces Avastin in China 62
Pfizer Japan Receives Clearance for Torisel in Japan 62
GSK Obtains European Commission's Conditional Marketing
Approval for Votrient 62
FDA Approves Tarceva® for Maintenance Treatment of NSCLC 62
FDA Approves GlaxoSmithKline's Votrient 63
European Commission Grants Clearance to Torisel for Mantle
Cell Lymphoma 63
Genetech Receives FDA Approval for Avastin in Renal Cell
Carcinoma 63
FDA Approves Bevacizumab as Second Line Treatment for
Glioblastoma 64
Novartis Obtains FDA Approval of Afinitor for Treating Renal
Cell Cancer 64
FDA Grants Clearance for Gleevec in Treatment of
Gastrointestinal Stromal Tumor 64
Celgene's Thalidomide Pharmion™ Receives EC Clearance for
Treating Multiple Myeloma 65
Genentech Obtains FDA Approval for Avastin in Breast Cancer 65
FDA Approves Nexavar for Treatment of Hepatocellular Carcinoma 65
Wyeth Receives EC Clearance for TORISEL in Advanced Renal Cell
Carcinoma 66
OSI and Roche Announce Approval of Tarceva® in Japan 66
ImClone Obtains FDA Label Expansion for Erbitux®, as Third
Line Therapy in mCRC 66
REVLIMID® Obtains Swissmedic Authorization in Switzerland 66
REVLIMID® Receives Marketing Approval in European Union 67
Wyeth Obtains FDA Clearance for Marketing Torisel 67
Chugai Obtains Approval for Avastin in Japan 67
Pfizer Obtains FDA Approval for Sunitinib in Metastatic Renal
Cell Carcinoma 68
FDA Approves Herceptin in HER2-Overexpressing Breast Cancer
Treatment 68
Genentech Receives FDA Approval for Bevacizumab in Non-Small
Cell Lung Cancer 68
Amgen Obtains FDA Approval for Vectibix Treating mCRC 69
FDA Grants Marketing Approval for Lucentis in Wet AMD 69
Celgene Obtains FDA Clearance for Revlimid in Multiple Myeloma 69
FDA Approves Bevacizumab for Second Line Treatment of
Metastatic Colorectal Cancer 70
Celgene Obtains FDA's Accelerated Approval for THALOMID 70
Celgene Obtains sNDA Approval for THALOMID from FDA 71
ImClone Obtains FDA Clearance for Erbitux® in the treatment of
SCCHN 71
Pfizer's Sutent Receives FDA Nod for Treatment of
Gastrointestinal Stromal Tumor 71
Celgene Receives FDA's Subpart H Approval for Revlimid in
Myelodysplastic Syndromes 72
US FDA Approves OSI's Tarceva® for Treating Pancreatic Carcinoma 72
OSI Obtains FDA Approval for Tarceva™ In the Treatment of NSCLC 73
FDA Grants Approval to Erbitux® in the Treatment of Metastatic
Colorectal Carcinoma 73
AstraZeneca Obtains FDA Approval for Iressa in NSCLC Treatment 74
9. RECENT INDUSTRY ACTIVITY 75
Genentech to Carry Out Additional Trial of Avastin in Her2-
negative mBC 75
Pfizer to Seek regulatory Clearance for Axitinib in Europe and US 75
FDA to Withdraw Avastin's Approval for Breast Cancer 75
Eyetech Receives QTDP Grant To Develop Extended- Release
Formulation of Macugen® 75
sanofi-aventis and Regeneron to Continue VELOUR Trial as Planned 76
EntreMed Enters into Financing Deal for ENMD-2076 Development 76
Chugai Pharmaceuticals Fulfills Condition for Avastin's Approval 76
Gilead Sciences to Take Over CGI Pharma 77
Mersana Commences XMT-1107 Phase I Clinical Trial 77
Astellas Pharma Acquires OSI Pharmaceuticals 77
Roche to Conduct a Trial on Anti-Cancer Antibody TB-403 77
Mersana Therapeutics Inks License Agreement With Teva 78
Acceleron Publishes Pre-clinical Data Study on ACE-041 78
Antisense Raises Capital to Continue Phase III Trabedersen Trial 78
GSK Receives Positive Opinions from EMEA for Two Cancer Medicines 79
EMEA Issues Positive Opinion on GSK's Votrient 79
EMEA Issues Positive Opinion on GSK's Anti Cancer Drug
Candidate, Tyverb 79
Abbott Enters into Licensing Agreement with Pierre Fabre 80
Arno Therapeutics Inks Global Licensing Agreement with OSU 80
BI Initiates Late Stage Clinical Trials for Two Oncology Drug
Candidates 80
AnGes Obtains US FDA Approval for Phase III Trial of Collategene™ 80
Silence Therapeutics and Intradigm Merge 81
Mersana Launches First Phase of XMT-1107 Clinical Trial 81
ImClone Receives Complete Response Letter for Erbitux® sBLA
From FDA 82
Oxigene Releases Encouraging Data from OXi4503 Pre-clinical
Studies 82
Potentia Enters into Licensing and Purchase Option Deal with
Alcon 83
Quark Receives Additional Patents for RTP 801 Gene Targeting
Compounds 83
Simcere Enters into Collaboration Deal with OSI Pharmaceuticals 84
Pfizer Acquires Wyeth in Cash & Stock Merger 84
Gene Signal Releases Interim Results from Phase II Study on
GS-101 84
Onco to Conduct Second Phase Trial of Fuso's OTS102 85
Green Cross Obtains US FDA Approval for Greenstatin Clinical
Trial 85
OXiGENE Acquire Symphony ViDA 85
Roche Releases Positive Results from Phase III Trial of Lucentis 86
Pfizer Halts Phase III Sutent Study for Colorectal Cancer 86
Morphotek Obtains FDA Clearance for MORAb-004 IND Application 86
GlaxoSmithKline Files MAA for Pazopanib in EU 87
Roche Acquires Genentech 87
Fuso Commences Phase II/III Clinical Trail for OTS102 87
EntreMed to Funnel Resources on ENMD-2076 Development 87
OmegaGenesis Enters Into Collaboration with Mayo Clinic for
Angiogenesis Research 88
Eli Lilly Acquires ImClone Systems 88
EntreMed Demonstrates Antitumor Effects of ENMD-2076 88
EntreMed Collaborates with JSB for ENMD-2076 Business Development 88
Circadian Technologies Limited Acquires Vegenics 89
Fuso and OTS to Initiate Phase II Trial for OTS102 89
EntreMed Releases Pre-Clinical Findings of ENMD-2076 in
Multiple Myeloma 89
Merck Serono Inks Development and Licensing Agreement with
Bionomics 90
Roche Inks Licensing Agreement with ThromboGenics and
BioInvent for TB-403 90
Aida Initiates Pre-Clinical Development of New Anti-Cancer Drug 91
Cyclacel Pharmaceuticals Releases Pre-Clinical Data of CYC116 91
Astellas and CoMentis Ink Agreement to Develop and
Commercialize Beta- Secretase Inhibitors 92
Kringle Pharma's NK4 Receives Patent Approval in Japan 92
UCB Releases Phase II Results of CDP791 in NSCLC Treatment 92
Celgene Takes Over Pharmion 92
REVLIMID® Obtains Orphan Drug Designation in Japan 93
TRACON Commences Phase I Clinical Trial on TRC105 93
Ark Therapeutics to Acquire Lymphatix 93
Access Takes Over Somanta 94
Pfizer Takes Over CovX 94
Callisto Restructures Licensing Agreement with Genzyme for
Atiprimod 94
EntreMed Receives FDA Approval for ENMD-2076 IND Application 95
EC Grants Orphan Medicinal Status to REVLIMID for Treatment of
CLC 95
Bristol-Myers Squibb Snaps Up Adnexus Therapeutics 95
Morvus Takes Over Two Companies 96
Merck Inks Agreement with BMS and ImClone for Erbitux®
Development And Commercialization 96
FDA Issues a Safety Labeling Update for Bevacizumab Drug 97
Fuso Initiates Phase I Clinical Study for OST102 Angiogenesis
Inhibitor 97
CRC to Support Bionomics in BN069 Development 97
Peregrine Secures Licensing Rights for B2GP1 Angiogenesis
Inhibitor 97
AnGes's Angiogenesis-Stimulating Drug Meets Primary End-Point
in Phase III Study 98
ImClone Annuls Development Agreement with UCB 98
ArQule Partners with Kyowa Hakko in Cancer Compound 98
Samaritan Snaps Up Metastatin Pharmaceuticals 98
EU Approves €2 Million Grants for VASOPLUS Consortium 99
MGH Cancer Center Reports Results of AZD2171 Phase II Trial 99
AVEO Inks Exclusive Licensing Agreement with Kirin for Novel
Anti-Cancer Compound 99
Sangamo and Edwards Ink Angiogenesis Asset Purchase Agreement 100
Covalon Secures Perfusion's Gene Therapy Solutions 100
Vical Strengthens Angiogenesis and Poloxamers IPR Portfolio 100
Biomira Takes Over ProIX Pharmaceuticals 100
FDA Gives Out Warning on Bevacizumab Drug 101
Athenagen Merges with Zapaq 101
Tigris Secures Global Licensing Rights to Develop and
Commercialize New Cancer Therapies 101
Bayer Yakuhin Files Marketing Application for Nexavar in Japan 101
Athenagen Purchases Assets of Osprey Pharmaceutical 102
Amgen Acquires Abgenix 102
Genmab Enters Exclusive Licensing Agreement with Bionomics 102
OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals 103
FDA Changes Labeling of Iressa, Limiting Use to NSCLC 103
Schering AG and Novartis Signs a Agreement to Commercialize
Angiogenesis Inhibitor, PTK787 103
Bausch & Lomb Signs an Option Agreement with PTC Therapeutics 104
Bausch & Lomb Receives License from Cephalon, Inc 104
Pharmacopeia Signs a Licensing Agreement with Allergan 104
Xantos Biomedicine and Cryptome Enters into Licensing Agreement 104
EntreMed Receives US Patent 105
FDA Issues Warning on Risks Associated with Bevacizumab 105
Compound Therapeutics Acquires Strategic Assets of Phylos 105
Sanofi Announces Plans to Acquire Aventis 105
ThromboGenics Enters into Collaborative Agreement with
Geymonat S.p.A. 105
AngioGenex Signs Development and Marketing Agreement with
BioCheck 106
Progen Industries Limited Bags Orphan Drug Status from US FDA 106
Regeneron Pharmaceuticals Initiates Phase I Clinical Trials
in Cancer 106
Roche Group to Undertake Expansion Program 106
Regeneron and Aventis Initiate a Clinical Development Program 106
EntreMed Signs Licensing Agreement with Celgene Corporation 106
Progen Industries Limited Receives EU Patent 107
Phylonix Pharmaceuticals Bags Phase II SBIR Grant 107
10. FOCUS ON SELECT GLOBAL PLAYERS 108
Abbott Laboratories (USA) 108
Adnexus Therapeutics, Inc. (USA) 108
Æterna Zentaris Inc. (Canada) 108
Amgen, Inc. (USA) 109
Angstrom Pharmaceuticals Inc. (USA) 109
AstraZeneca Plc. (UK) 110
Bayer HealthCare AG (Germany) 110
Callisto Pharmaceuticals, Inc. (USA) 111
Celgene Corporation (USA) 112
Celltech Group Plc. (UK) 112
Cephalon Inc. (USA) 112
Eisai Inc. (USA) 113
Eli Lilly And Company (USA) 113
ImClone Systems Inc. (USA) 114
EntreMed Inc. (USA) 114
GenVec Inc. (USA) 115
Genzyme Corp. (USA) 115
GlaxoSmithKline plc (UK) 116
Merck KGaA (Germany) 116
Novartis (Switzerland) 117
OSI Pharmaceuticals, Inc. (USA) 117
Eyetech, Inc. (USA) 118
Pfizer Inc. (USA) 119
Progen Industries (Australia) 119
Regeneron Pharmaceuticals 120
Roche (Switzerland) 121
Genentech Inc. (USA) 122
Chugai Pharmaceutical Co. Ltd. (Japan) 122
Silence Therapeutics 123
ThromboGenics Limited (Ireland) 123
11. GLOBAL MARKET PERSPECTIVE 125
Table 8: World Recent Past, Current & Future Analysis for
Angiogenesis Inhibitors & Stimulators by Geographic
Region/Country - US, Europe and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2003 through 2010 (includes corresponding Graph/Chart) 125
Table 9: World Historic Review for Angiogenesis Inhibitors &
Stimulators by Geographic Region/Country - US, Europe and
Rest of World Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 126
Table 10: World 11-Year Perspective for Angiogenesis
Inhibitors & Stimulators by Geographic Region/Country -
Percentage Breakdown of Dollar Sales for US, Europe and Rest
of World Markets for Years 2005, 2010 and 2015 (includes
corresponding Graph/Chart) 126
Table 11: World Recent Past, Current & Future Analysis for
Angiogenesis Inhibitors by Geographic Region/Country - US,
Europe and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2009 through 2015
(includes corresponding Graph/Chart) 127
Table 12: World Historic Review for Angiogenesis Inhibitors by
Geographic Region / Country - US, Europe and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) 128
Table 13: World 11-Year Perspective for Angiogenesis
Inhibitors by Geographic Region/Country - Percentage Breakdown
of Dollar Sales for US, Europe and Rest of World Markets for
Years 2005, 2010 and 2015 (includes corresponding Graph/Chart) 128
Table 14: World Recent Past, Current & Future Analysis for
Angiogenesis Stimulators by Geographic Region/Country - US,
Europe and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2009 through 2015
(includes corresponding Graph/Chart) 129
Table 15: World Historic Review for Angiogenesis Stimulators
by Geographic Region / Country - US, Europe and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) 130
Table 16: World 11-Year Perspective for Angiogenesis
Stimulators by Geographic Region/Country - Percentage
Breakdown of Dollar Sales for US, Europe and Rest of World
Markets for Years 2005, 2010 and 2015 (includes corresponding
Graph/Chart) 130
12. THE UNITED STATES 131
A.Market Analysis 131
US Spearheading the Angiogenesis Market 131
Angiogenic Inhibitors 131
List of FDA Approved Anti-Angiogenic Drugs 131
Pipeline Status By Disease 133
Anti-Angiogenesis Therapeutics In Phase III Development
for Renal Cell Carcinoma 133
Anti-Angiogenesis Therapeutics In Phase III Development
for Breast Cancer Treatment 133
Angiogenesis Stimulators 134
Historical Market Snapshots 134
Market Influencers 135
Types of Drug Approvals 135
New Drug Approval (NDA) 135
Orphan Drug Act 135
Benefits Derived on Successful Grant of 135
Orphan Drug Status 135
Angiogenesis Foundation 135
Key Role of the Foundation in Angiogenesis 136
The Rising Concern 136
Cancer 136
Cancer Statistics in US 136
A Picture of Colon Cancer in the US 136
Pancreatic Cancer 136
Vital Statistics 137
Table 17: New Cancer Cases in the US By Affected Site:
2009 137
Table 18: New Cancer Cases in Males in US by Leading
Site: 2009 (includes corresponding Graph/Chart) 139
Table 19: New Cancer Cases in Females in US by Leading
Site:2009 (includes corresponding Graph/Chart) 140
Table 20: Cancer Related Deaths in the US By Affected
Site:2009 141
Table 21: Cancer Related Deaths in Males in US by Leading
Site: 2009 (includes corresponding Graph/Chart) 143
Table 22: Cancer Related Deaths in Females in US by
Leading Site: 2009 (includes corresponding Graph/Chart) 144
AMD and DME Incidence in the US 144
Rheumatoid Arthritis: Another Emerging Threat 144
Diabetic Retinopathy 145
Coronary Artery Disease (CAD) 145
Myocardial Infarction Statistics in the US 145
Peripheral Arterial Disease 145
B.Market Analytics 146
Table 23: US Recent Past, Current & Future Analysis for
Angiogenesis Inhibitors & Stimulators by Product
Segments-Angiogenesis Inhibitors and Angiogenesis
Stimulators Markets Independently Analyzed with Annual
Revenues in US$ Million for Years 2009 through 2015
(includes corresponding Graph/Chart) 146
Table 24: US Historic Review for Angiogenesis Inhibitors &
Stimulators by Product Segments- Angiogenesis Inhibitors and
Angiogenesis Stimulators Markets Independently Analyzed
with Annual Revenues in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) 147
Table 25: US 11-Year Perspective for Angiogenesis
Inhibitors & Stimulators by Product Segments - Percentage
Breakdown of Dollar Sales for Angiogenesis Inhibitors &
Stimulators for Years 2005, 2010 and 2015 147
13. EUROPE 148
A.Market Analysis 148
Facet of Angiogenesis in the European Market 148
Angiogenesis Market - A Historic Perspective 148
Cancer Trends 148
Table 26: Cancer Incidence in Europe by Site (2009)
(includes corresponding Graph/Chart) 149
B.Market Analytics 150
Table 27: European Recent Past, Current & Future Analysis
for Angiogenesis Inhibitors & Stimulators by Product
Segments-Angiogenesis Inhibitors and Angiogenesis
Stimulators Markets Independently Analyzed with Annual
Revenues in US$ Million for Years 2009 through 2015
(includes corresponding Graph/Chart) 150
Table 28: European Historic Review for Angiogenesis
Inhibitors & Stimulators by Product Segments- Angiogenesis
Inhibitors and Angiogenesis Stimulators Markets
Independently Analyzed with Annual Revenues in US$ Million
for Years 2003 through 2008 (includes corresponding
Graph/Chart) 151
Table 29: European 11-Year Perspective for Angiogenesis
Inhibitors & Stimulators by Product Segments - Percentage
Breakdown of Dollar Sales for Angiogenesis Inhibitors &
Stimulators for Years 2005, 2010 and 2015 151
14. REST OF WORLD 152
A.Market Analysis 152
Angiogenesis Market - Making a Positive Move 152
Japanese Market 152
Quest for New Opportunities 152
B.Market Analytics 153
Table 30: Rest of World Recent Past, Current & Future
Analysis for Angiogenesis Inhibitors & Stimulators by
Product Segments-Angiogenesis Inhibitors and Angiogenesis
Stimulators Markets Independently Analyzed with Annual
Revenues in US$ Million for Years 2009 through 2015
(includes corresponding Graph/Chart) 153
Table 31: Rest of World Historic Review for Angiogenesis
Inhibitors & Stimulators by Product Segments- Angiogenesis
Inhibitors and Angiogenesis Stimulators Markets
Independently Analyzed with Annual Revenues in US$ Million
for Years 2003 through 2008 (includes corresponding
Graph/Chart) 154
Table 32: Rest of World 11-Year Perspective for Angiogenesis
Inhibitors & Stimulators by Product Segments - Percentage
Breakdown of Dollar Sales for Angiogenesis Inhibitors &
Stimulators for Years 2005, 2010 and 2015 154
COMPETITIVE LANDSCAPE
Total Companies Profiled: 72 (including Divisions/Subsidiaries - 84)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 50
Canada 2
Japan 3
Europe 21
France 2
Germany 5
The United Kingdom 5
Italy 3
Rest of Europe 6
Asia-Pacific (Excluding Japan) 8
------------------------------------------
To order this report:
: Global Angiongenesis Inhibitors and Stimulators Industry
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
Global Angiongenesis Inhibitors and Stimulators Industry
http://www.reportlinker.com/p0459142/Global-Angiongenesis-Inhibitors-and-Stimulators-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Advertisement
This report analyzes the worldwide markets for Angiogenesis Inhibitors and Stimulators in US$ Million by the following product segments - Angiogenesis Inhibitors, and Angiogenesis Stimulators. Annual estimates and forecasts are provided for the period 2007 through 2015. Also, a seven-year historic analysis is provided for these markets. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Middle East, and Latin America. The report profiles 72 companies including many key and niche players worldwide such as Abbott Laboratories, Adnexus Therapeutics, Inc., Æterna Zentaris Inc., Amgen, Inc., Angstrom Pharmaceuticals Inc., AstraZeneca Plc, Bayer HealthCare AG, Callisto Pharmaceuticals, Inc., Celgene Corporation, Celltech Group Plc., Cephalon Inc., Eisai Inc., Eli Lilly And Company, ImClone Systems Inc., EntreMed Inc., GenVec Inc., Genzyme Corp., GlaxoSmithKline plc, Merck KGaA, Novartis, OSI Pharmaceuticals, Inc., Eyetech, Inc., Pfizer Inc., Progen Industries, Regeneron Pharmaceuticals, Roche, Genentech Inc., Chugai Pharmaceutical Co. Ltd., Silence Therapeutics, and ThromboGenics Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1
Study Reliability And Reporting Limitations 1
Disclaimers 2
Data Interpretation & Reporting Level 3
Quantitative Techniques & Analytics 3
Product Definitions And Scope Of Study 3
1. Angiogenesis Inhibitors 4
2. Angiogenesis Stimulators 4
2. MARKET OUTLOOK 5
Angiogenesis: In the Spotlight 5
Angiogenesis: A Preview 5
Analysis by Region 5
US: The Single Largest Market 5
Angiogenesis Regulating Products Market in Europe 6
Market for Angiogenesis Regulating Products in Rest of World 6
Table 1: Global Market for Angiogenesis Regulating Products
(2009-2015): Geographic Regions Ranked by CAGR - USA,
Europe, and Rest of World (includes corresponding
Graph/Chart) 6
Selective Analysis of Angiogenesis Regulating Products 6
3. MARKET OVERVIEW 7
Angiogenesis Makes Inroads 7
Angiogenesis: Ushering-In a New Era 7
Angiogenesis: Fact File 8
Milestones in Research Achieved Over the Years 9
Anti-Angiogenic Drugs Market - An Overview 10
Angiogenic Inhibitors Market to Surge 10
The Long Journey for Anti-Angiogenesis Therapies 10
Approved Anti-Angiogenesis Drugs in the Market 11
Select FDA-Approved Anti-Angiogenic Drugs/ Therapeutics In
Oncology By Type 11
Small Molecule Tyrosine Kinase Inhibitors 12
Inhibitors of mTOR 13
Other Anti-Angiogenic Agents 13
Leading Drugs in the Market 14
Avastin Leads the Fray 14
Table 2: Select Leading Drugs in the Global
Anti-Angiogenesis Market: Annual Sales in US$ Million for
Years 2008 & 2009 (includes corresponding Graph/Chart) 14
Overview of Select Leading Drugs 15
Avastin 15
Survival Benefit Conferred by Avastin 16
Mechanism of Action 17
General Mode of Delivery 17
Side Effects Elicited on Administering Avastin 17
ERBITUX™ (Cetuximab) 17
Regulatory Approvals 18
Erbitux in Head and Neck Cancer 18
Glivec/Gleevec (imatinib mesylate) 19
Herceptin (Tractuzumab) 19
Iressa (gefitinib) 19
Sutent (Sunitinib) 20
Other Regulatory Approvals 20
Sunitinib in Various Indications 20
Sunitinib in Renal Cell Carcinoma (RCC) 20
Sutent in Gastrointestinal Stromal Tumors 21
Cost Related Issues 21
Tarceva (Erlotinib) 21
Other Regulatory Approvals 22
Thalomid® (thalidomide) 22
Table 3: Thalomid - Percentage Breakdown Based on Relative
Oncology Application (includes corresponding Graph/Chart) 22
Cilengitide 23
Imiquimod 23
Angiogenesis Inhibitors - Pipeline Status 24
Select Anti-Angiogenesis Drugs in Phase III Development 24
Select Anti-Angiogenesis Drugs in Phase II Development 25
Select Anti-Angiogenesis Drugs in Phase I Development 26
Approved and Pipeline Indications of Select Anti-VEGF/VEGFR
Drugs 26
Novel Targets for Anti-Angiogenic Activity 27
Approved and Pipeline HER Receptor-Targeting Drugs 28
Select Approved and Pipeline m-TOR Inhibitors 28
Integrins 28
Select Integrin Targeting Drugs Under Development 29
Angiogenic Inhibitors - By Disease Application 29
Cancer 29
Various Types of Cancers Targeted by Angiogenesis
Inhibitors in Phase III Clinical Development 29
Diabetic Retinopathy 30
Female Reproductive Cycle 30
Psoriasis 30
Inflammatory Diseases 30
Table 4: Classification of Anti-Angiogenic Compounds Based
on Most Commonly Targeted Indication (includes
corresponding Graph/Chart) 31
Angiogenesis Inhibitors in Eye Related Diseases 31
Age-Related Macular Degeneration 31
Wet AMD 32
Dry AMD 32
Select Anti-Angiogenic Drugs Approved by FDA for Treatment
of Eye Diseases 32
Angiogenesis Inhibitors in Dermatology 33
Select Drugs/Therapeutics with Angiogenic Mode of Action
Approved by FDA for Dermatology 33
4. MARKET TRENDS 34
Cancer - The Key Target Indication for Research in Anti-
Angiogeneis Drugs 34
Avastin Continues to Record Robust Growth 34
New Markets Offer Higher Potential for Herceptin 34
Increased Use Drives Tarceva's Growth in Developed Markets 34
Angiogenesis Inhibitors Continue to Dominate RCC Drug Market 35
Votrient to Lead Renal Cell Carcinoma (RCC) Drug Market 35
Table 5: Leading Drugs in the Global Second Line Advanced
Renal Cell Carcinoma Market (2009): Percentage Breakdown by
Value Sales for Nexavar, Torisel, Afinitor, Avastin, and
Others (includes corresponding Graph/Chart) 36
Clinical Benefits of Votrient Over Sutent 36
Avastin's Approval for Breast Cancer Treatment Under Threat 37
5. ANGIOGENESIS REPERTOIRE 38
An In-depth Insight into Angiogenesis 38
Angiogenesis: At a Glance 38
Requisites for Angiogenesis 38
Endogenous Regulators of Angiogenesis 39
Angiogenic Process: Sequence of Events 39
Angiogenesis Process in Children 40
Angiogenesis Process in Adults 40
The Process of Angiogenesis in Thyroid Gland 40
6. ANGIOGENESIS INHIBITORS 41
Table 6: Global Market for Angiogenesis Inhibitors
(2009-2015): Geographic Regions Ranked by CAGR - USA, Europe,
and Rest of World (includes corresponding Graph/Chart) 41
Angiogenic Inhibitors: Basic Framework 41
Natural Inhibitors 41
Thrombospondin 41
Interferon 41
Cryptic Inhibitors 42
Other Natural Inhibitors 42
Natural Sources for Anti-Angiogenic Action 42
Potential Anti-Angiogenic Drugs of Natural Origin 42
Angiogenic Inhibitors: On the Verge of Attaining Superior
Clinical Efficacy 42
Endogenous vs Synthetic Agents 43
Angiogenesis Inhibitors: Classification Based on Source of
Origin 43
Anti-Angiogenic Molecules: Classification Based on Mode of
Action 44
Broad Overview of Anti-Angiogenic Therapies 44
Pre-Requisites for Any Drug to be an Angiogenic Inhibitor 44
Specific Therapeutic Strategies of Anti- Angiogenesis Agents 45
Inhibiting Angiogenesis In Vivo 45
Antiangiogenic Tumor Therapy 46
Antivascular Therapy: Adding a New Dimension 46
MMPs - Exhibiting Dual Role 46
Angiogenesis Inhibitors Vs Standard Chemotherapy 47
Comparison Between Cytostatic Antiangiogenesis and Cytotoxic
Chemotherapy 47
Proteoglycan Mixture: Therapeutic Powerhouse 47
Features of VascuStatin 48
Angiogenesis Inhibition Versus Cytotoxic Therapy 48
Relationship Between Copper and Angiogenesis 48
Anti-Angiogenesis Action of Pencillamine 48
Outline of Steps Involved in Drug Discovery for Angiogenesis 49
Drug Delivery: Their Influence on Therapeutics 49
7. PROMOTERS OF ANGIOGENESIS/ ANGIOGENESIS STIMULATORS 51
Angiogenesis Stimulators 51
Growth Factors 51
Angiogenic Stimulators in the Market 51
Table 7: Global Market for Angiogenesis Stimulators
(2009-2015): Geographic Regions Ranked by CAGR -USA, Europe,
and Rest of World (includes corresponding Graph/Chart) 51
Stimulators Exhibiting Profound Influence on Angiogenesis 51
Vascular Endothelial Growth Factor (VEGF) 51
VEGF and Their Influence on Diabetes and Diabetic Retinopathy 52
Fibroblast Growth Factors (FGFs) 52
Basic Fibroblast Growth Factor (bFGF) 52
Placental Growth Factor (PlGF) 52
Recombinant a4 Fragment 53
Hepatocyte Growth Factor/ Scatter Factor (HGF/SF) 53
Angiogenin 53
Platelet Derived Endothelial Cell Growth Factor 53
Applications of Angiogenic Stimulators vis-à-vis Disease
Perspective 53
Cardiac Diseases 53
Wound Healing and Burns 54
Critical Limb Ischaemia 54
Status of Angiogenic Inducers 54
Angiogenic Therapies for Tissue Repair & Regeneration 54
Select Devices Supporting Therapeutic Angiogenesis 55
Angiogenesis in Ischemic Heart 55
Factors Influencing Ischemic Angiogenesis 55
Angiogenesis and CAD 55
Angiogenesis in Wound Healing 56
Factors Stimulating Wound Angiogenesis 56
Factors Impairing Wound Angiogenesis 56
Angiogenic Therapy Vs Conventional Therapy 57
Types of Angiogensesis 57
Excessive Angiogenesis 57
Insufficient Angiogenesis 57
Tumor Angiogenesis 57
Sequence of Actions 57
Angiogenesis and Tumor Progression 58
Oncogenes vis-à-vis Potential Pro-angiogenic Activities on
Tumor Angiogenesis 58
Role of Angiogenesis in Skin Diseases 58
Current State of Select Drugs & Their Targeted Application 59
Analysis of Developmental Activities Between Decades 59
Role of Enzymes and Inflammatory Cells in Angiogenesis 60
Angiogenic Imbalance Augments Retinal Neovascularization 60
Oncogenes & VE -cadherin - A Facilitating Role 60
8. PRODUCT APPROVALS AND LAUNCHES 61
Pfizer Obtains European Approval for SUTENT® to Treat
Pancreatic NET 61
Novartis Obtains FDA Approval of New Indication for Afinitor 61
FDA Approves Herceptin for Treating Metastatic Adenocarcinoma 61
Roche Introduces Avastin in China 62
Pfizer Japan Receives Clearance for Torisel in Japan 62
GSK Obtains European Commission's Conditional Marketing
Approval for Votrient 62
FDA Approves Tarceva® for Maintenance Treatment of NSCLC 62
FDA Approves GlaxoSmithKline's Votrient 63
European Commission Grants Clearance to Torisel for Mantle
Cell Lymphoma 63
Genetech Receives FDA Approval for Avastin in Renal Cell
Carcinoma 63
FDA Approves Bevacizumab as Second Line Treatment for
Glioblastoma 64
Novartis Obtains FDA Approval of Afinitor for Treating Renal
Cell Cancer 64
FDA Grants Clearance for Gleevec in Treatment of
Gastrointestinal Stromal Tumor 64
Celgene's Thalidomide Pharmion™ Receives EC Clearance for
Treating Multiple Myeloma 65
Genentech Obtains FDA Approval for Avastin in Breast Cancer 65
FDA Approves Nexavar for Treatment of Hepatocellular Carcinoma 65
Wyeth Receives EC Clearance for TORISEL in Advanced Renal Cell
Carcinoma 66
OSI and Roche Announce Approval of Tarceva® in Japan 66
ImClone Obtains FDA Label Expansion for Erbitux®, as Third
Line Therapy in mCRC 66
REVLIMID® Obtains Swissmedic Authorization in Switzerland 66
REVLIMID® Receives Marketing Approval in European Union 67
Wyeth Obtains FDA Clearance for Marketing Torisel 67
Chugai Obtains Approval for Avastin in Japan 67
Pfizer Obtains FDA Approval for Sunitinib in Metastatic Renal
Cell Carcinoma 68
FDA Approves Herceptin in HER2-Overexpressing Breast Cancer
Treatment 68
Genentech Receives FDA Approval for Bevacizumab in Non-Small
Cell Lung Cancer 68
Amgen Obtains FDA Approval for Vectibix Treating mCRC 69
FDA Grants Marketing Approval for Lucentis in Wet AMD 69
Celgene Obtains FDA Clearance for Revlimid in Multiple Myeloma 69
FDA Approves Bevacizumab for Second Line Treatment of
Metastatic Colorectal Cancer 70
Celgene Obtains FDA's Accelerated Approval for THALOMID 70
Celgene Obtains sNDA Approval for THALOMID from FDA 71
ImClone Obtains FDA Clearance for Erbitux® in the treatment of
SCCHN 71
Pfizer's Sutent Receives FDA Nod for Treatment of
Gastrointestinal Stromal Tumor 71
Celgene Receives FDA's Subpart H Approval for Revlimid in
Myelodysplastic Syndromes 72
US FDA Approves OSI's Tarceva® for Treating Pancreatic Carcinoma 72
OSI Obtains FDA Approval for Tarceva™ In the Treatment of NSCLC 73
FDA Grants Approval to Erbitux® in the Treatment of Metastatic
Colorectal Carcinoma 73
AstraZeneca Obtains FDA Approval for Iressa in NSCLC Treatment 74
9. RECENT INDUSTRY ACTIVITY 75
Genentech to Carry Out Additional Trial of Avastin in Her2-
negative mBC 75
Pfizer to Seek regulatory Clearance for Axitinib in Europe and US 75
FDA to Withdraw Avastin's Approval for Breast Cancer 75
Eyetech Receives QTDP Grant To Develop Extended- Release
Formulation of Macugen® 75
sanofi-aventis and Regeneron to Continue VELOUR Trial as Planned 76
EntreMed Enters into Financing Deal for ENMD-2076 Development 76
Chugai Pharmaceuticals Fulfills Condition for Avastin's Approval 76
Gilead Sciences to Take Over CGI Pharma 77
Mersana Commences XMT-1107 Phase I Clinical Trial 77
Astellas Pharma Acquires OSI Pharmaceuticals 77
Roche to Conduct a Trial on Anti-Cancer Antibody TB-403 77
Mersana Therapeutics Inks License Agreement With Teva 78
Acceleron Publishes Pre-clinical Data Study on ACE-041 78
Antisense Raises Capital to Continue Phase III Trabedersen Trial 78
GSK Receives Positive Opinions from EMEA for Two Cancer Medicines 79
EMEA Issues Positive Opinion on GSK's Votrient 79
EMEA Issues Positive Opinion on GSK's Anti Cancer Drug
Candidate, Tyverb 79
Abbott Enters into Licensing Agreement with Pierre Fabre 80
Arno Therapeutics Inks Global Licensing Agreement with OSU 80
BI Initiates Late Stage Clinical Trials for Two Oncology Drug
Candidates 80
AnGes Obtains US FDA Approval for Phase III Trial of Collategene™ 80
Silence Therapeutics and Intradigm Merge 81
Mersana Launches First Phase of XMT-1107 Clinical Trial 81
ImClone Receives Complete Response Letter for Erbitux® sBLA
From FDA 82
Oxigene Releases Encouraging Data from OXi4503 Pre-clinical
Studies 82
Potentia Enters into Licensing and Purchase Option Deal with
Alcon 83
Quark Receives Additional Patents for RTP 801 Gene Targeting
Compounds 83
Simcere Enters into Collaboration Deal with OSI Pharmaceuticals 84
Pfizer Acquires Wyeth in Cash & Stock Merger 84
Gene Signal Releases Interim Results from Phase II Study on
GS-101 84
Onco to Conduct Second Phase Trial of Fuso's OTS102 85
Green Cross Obtains US FDA Approval for Greenstatin Clinical
Trial 85
OXiGENE Acquire Symphony ViDA 85
Roche Releases Positive Results from Phase III Trial of Lucentis 86
Pfizer Halts Phase III Sutent Study for Colorectal Cancer 86
Morphotek Obtains FDA Clearance for MORAb-004 IND Application 86
GlaxoSmithKline Files MAA for Pazopanib in EU 87
Roche Acquires Genentech 87
Fuso Commences Phase II/III Clinical Trail for OTS102 87
EntreMed to Funnel Resources on ENMD-2076 Development 87
OmegaGenesis Enters Into Collaboration with Mayo Clinic for
Angiogenesis Research 88
Eli Lilly Acquires ImClone Systems 88
EntreMed Demonstrates Antitumor Effects of ENMD-2076 88
EntreMed Collaborates with JSB for ENMD-2076 Business Development 88
Circadian Technologies Limited Acquires Vegenics 89
Fuso and OTS to Initiate Phase II Trial for OTS102 89
EntreMed Releases Pre-Clinical Findings of ENMD-2076 in
Multiple Myeloma 89
Merck Serono Inks Development and Licensing Agreement with
Bionomics 90
Roche Inks Licensing Agreement with ThromboGenics and
BioInvent for TB-403 90
Aida Initiates Pre-Clinical Development of New Anti-Cancer Drug 91
Cyclacel Pharmaceuticals Releases Pre-Clinical Data of CYC116 91
Astellas and CoMentis Ink Agreement to Develop and
Commercialize Beta- Secretase Inhibitors 92
Kringle Pharma's NK4 Receives Patent Approval in Japan 92
UCB Releases Phase II Results of CDP791 in NSCLC Treatment 92
Celgene Takes Over Pharmion 92
REVLIMID® Obtains Orphan Drug Designation in Japan 93
TRACON Commences Phase I Clinical Trial on TRC105 93
Ark Therapeutics to Acquire Lymphatix 93
Access Takes Over Somanta 94
Pfizer Takes Over CovX 94
Callisto Restructures Licensing Agreement with Genzyme for
Atiprimod 94
EntreMed Receives FDA Approval for ENMD-2076 IND Application 95
EC Grants Orphan Medicinal Status to REVLIMID for Treatment of
CLC 95
Bristol-Myers Squibb Snaps Up Adnexus Therapeutics 95
Morvus Takes Over Two Companies 96
Merck Inks Agreement with BMS and ImClone for Erbitux®
Development And Commercialization 96
FDA Issues a Safety Labeling Update for Bevacizumab Drug 97
Fuso Initiates Phase I Clinical Study for OST102 Angiogenesis
Inhibitor 97
CRC to Support Bionomics in BN069 Development 97
Peregrine Secures Licensing Rights for B2GP1 Angiogenesis
Inhibitor 97
AnGes's Angiogenesis-Stimulating Drug Meets Primary End-Point
in Phase III Study 98
ImClone Annuls Development Agreement with UCB 98
ArQule Partners with Kyowa Hakko in Cancer Compound 98
Samaritan Snaps Up Metastatin Pharmaceuticals 98
EU Approves €2 Million Grants for VASOPLUS Consortium 99
MGH Cancer Center Reports Results of AZD2171 Phase II Trial 99
AVEO Inks Exclusive Licensing Agreement with Kirin for Novel
Anti-Cancer Compound 99
Sangamo and Edwards Ink Angiogenesis Asset Purchase Agreement 100
Covalon Secures Perfusion's Gene Therapy Solutions 100
Vical Strengthens Angiogenesis and Poloxamers IPR Portfolio 100
Biomira Takes Over ProIX Pharmaceuticals 100
FDA Gives Out Warning on Bevacizumab Drug 101
Athenagen Merges with Zapaq 101
Tigris Secures Global Licensing Rights to Develop and
Commercialize New Cancer Therapies 101
Bayer Yakuhin Files Marketing Application for Nexavar in Japan 101
Athenagen Purchases Assets of Osprey Pharmaceutical 102
Amgen Acquires Abgenix 102
Genmab Enters Exclusive Licensing Agreement with Bionomics 102
OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals 103
FDA Changes Labeling of Iressa, Limiting Use to NSCLC 103
Schering AG and Novartis Signs a Agreement to Commercialize
Angiogenesis Inhibitor, PTK787 103
Bausch & Lomb Signs an Option Agreement with PTC Therapeutics 104
Bausch & Lomb Receives License from Cephalon, Inc 104
Pharmacopeia Signs a Licensing Agreement with Allergan 104
Xantos Biomedicine and Cryptome Enters into Licensing Agreement 104
EntreMed Receives US Patent 105
FDA Issues Warning on Risks Associated with Bevacizumab 105
Compound Therapeutics Acquires Strategic Assets of Phylos 105
Sanofi Announces Plans to Acquire Aventis 105
ThromboGenics Enters into Collaborative Agreement with
Geymonat S.p.A. 105
AngioGenex Signs Development and Marketing Agreement with
BioCheck 106
Progen Industries Limited Bags Orphan Drug Status from US FDA 106
Regeneron Pharmaceuticals Initiates Phase I Clinical Trials
in Cancer 106
Roche Group to Undertake Expansion Program 106
Regeneron and Aventis Initiate a Clinical Development Program 106
EntreMed Signs Licensing Agreement with Celgene Corporation 106
Progen Industries Limited Receives EU Patent 107
Phylonix Pharmaceuticals Bags Phase II SBIR Grant 107
10. FOCUS ON SELECT GLOBAL PLAYERS 108
Abbott Laboratories (USA) 108
Adnexus Therapeutics, Inc. (USA) 108
Æterna Zentaris Inc. (Canada) 108
Amgen, Inc. (USA) 109
Angstrom Pharmaceuticals Inc. (USA) 109
AstraZeneca Plc. (UK) 110
Bayer HealthCare AG (Germany) 110
Callisto Pharmaceuticals, Inc. (USA) 111
Celgene Corporation (USA) 112
Celltech Group Plc. (UK) 112
Cephalon Inc. (USA) 112
Eisai Inc. (USA) 113
Eli Lilly And Company (USA) 113
ImClone Systems Inc. (USA) 114
EntreMed Inc. (USA) 114
GenVec Inc. (USA) 115
Genzyme Corp. (USA) 115
GlaxoSmithKline plc (UK) 116
Merck KGaA (Germany) 116
Novartis (Switzerland) 117
OSI Pharmaceuticals, Inc. (USA) 117
Eyetech, Inc. (USA) 118
Pfizer Inc. (USA) 119
Progen Industries (Australia) 119
Regeneron Pharmaceuticals 120
Roche (Switzerland) 121
Genentech Inc. (USA) 122
Chugai Pharmaceutical Co. Ltd. (Japan) 122
Silence Therapeutics 123
ThromboGenics Limited (Ireland) 123
11. GLOBAL MARKET PERSPECTIVE 125
Table 8: World Recent Past, Current & Future Analysis for
Angiogenesis Inhibitors & Stimulators by Geographic
Region/Country - US, Europe and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2003 through 2010 (includes corresponding Graph/Chart) 125
Table 9: World Historic Review for Angiogenesis Inhibitors &
Stimulators by Geographic Region/Country - US, Europe and
Rest of World Markets Independently Analyzed with Annual Sales
in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) 126
Table 10: World 11-Year Perspective for Angiogenesis
Inhibitors & Stimulators by Geographic Region/Country -
Percentage Breakdown of Dollar Sales for US, Europe and Rest
of World Markets for Years 2005, 2010 and 2015 (includes
corresponding Graph/Chart) 126
Table 11: World Recent Past, Current & Future Analysis for
Angiogenesis Inhibitors by Geographic Region/Country - US,
Europe and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2009 through 2015
(includes corresponding Graph/Chart) 127
Table 12: World Historic Review for Angiogenesis Inhibitors by
Geographic Region / Country - US, Europe and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) 128
Table 13: World 11-Year Perspective for Angiogenesis
Inhibitors by Geographic Region/Country - Percentage Breakdown
of Dollar Sales for US, Europe and Rest of World Markets for
Years 2005, 2010 and 2015 (includes corresponding Graph/Chart) 128
Table 14: World Recent Past, Current & Future Analysis for
Angiogenesis Stimulators by Geographic Region/Country - US,
Europe and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2009 through 2015
(includes corresponding Graph/Chart) 129
Table 15: World Historic Review for Angiogenesis Stimulators
by Geographic Region / Country - US, Europe and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) 130
Table 16: World 11-Year Perspective for Angiogenesis
Stimulators by Geographic Region/Country - Percentage
Breakdown of Dollar Sales for US, Europe and Rest of World
Markets for Years 2005, 2010 and 2015 (includes corresponding
Graph/Chart) 130
12. THE UNITED STATES 131
A.Market Analysis 131
US Spearheading the Angiogenesis Market 131
Angiogenic Inhibitors 131
List of FDA Approved Anti-Angiogenic Drugs 131
Pipeline Status By Disease 133
Anti-Angiogenesis Therapeutics In Phase III Development
for Renal Cell Carcinoma 133
Anti-Angiogenesis Therapeutics In Phase III Development
for Breast Cancer Treatment 133
Angiogenesis Stimulators 134
Historical Market Snapshots 134
Market Influencers 135
Types of Drug Approvals 135
New Drug Approval (NDA) 135
Orphan Drug Act 135
Benefits Derived on Successful Grant of 135
Orphan Drug Status 135
Angiogenesis Foundation 135
Key Role of the Foundation in Angiogenesis 136
The Rising Concern 136
Cancer 136
Cancer Statistics in US 136
A Picture of Colon Cancer in the US 136
Pancreatic Cancer 136
Vital Statistics 137
Table 17: New Cancer Cases in the US By Affected Site:
2009 137
Table 18: New Cancer Cases in Males in US by Leading
Site: 2009 (includes corresponding Graph/Chart) 139
Table 19: New Cancer Cases in Females in US by Leading
Site:2009 (includes corresponding Graph/Chart) 140
Table 20: Cancer Related Deaths in the US By Affected
Site:2009 141
Table 21: Cancer Related Deaths in Males in US by Leading
Site: 2009 (includes corresponding Graph/Chart) 143
Table 22: Cancer Related Deaths in Females in US by
Leading Site: 2009 (includes corresponding Graph/Chart) 144
AMD and DME Incidence in the US 144
Rheumatoid Arthritis: Another Emerging Threat 144
Diabetic Retinopathy 145
Coronary Artery Disease (CAD) 145
Myocardial Infarction Statistics in the US 145
Peripheral Arterial Disease 145
B.Market Analytics 146
Table 23: US Recent Past, Current & Future Analysis for
Angiogenesis Inhibitors & Stimulators by Product
Segments-Angiogenesis Inhibitors and Angiogenesis
Stimulators Markets Independently Analyzed with Annual
Revenues in US$ Million for Years 2009 through 2015
(includes corresponding Graph/Chart) 146
Table 24: US Historic Review for Angiogenesis Inhibitors &
Stimulators by Product Segments- Angiogenesis Inhibitors and
Angiogenesis Stimulators Markets Independently Analyzed
with Annual Revenues in US$ Million for Years 2003 through
2008 (includes corresponding Graph/Chart) 147
Table 25: US 11-Year Perspective for Angiogenesis
Inhibitors & Stimulators by Product Segments - Percentage
Breakdown of Dollar Sales for Angiogenesis Inhibitors &
Stimulators for Years 2005, 2010 and 2015 147
13. EUROPE 148
A.Market Analysis 148
Facet of Angiogenesis in the European Market 148
Angiogenesis Market - A Historic Perspective 148
Cancer Trends 148
Table 26: Cancer Incidence in Europe by Site (2009)
(includes corresponding Graph/Chart) 149
B.Market Analytics 150
Table 27: European Recent Past, Current & Future Analysis
for Angiogenesis Inhibitors & Stimulators by Product
Segments-Angiogenesis Inhibitors and Angiogenesis
Stimulators Markets Independently Analyzed with Annual
Revenues in US$ Million for Years 2009 through 2015
(includes corresponding Graph/Chart) 150
Table 28: European Historic Review for Angiogenesis
Inhibitors & Stimulators by Product Segments- Angiogenesis
Inhibitors and Angiogenesis Stimulators Markets
Independently Analyzed with Annual Revenues in US$ Million
for Years 2003 through 2008 (includes corresponding
Graph/Chart) 151
Table 29: European 11-Year Perspective for Angiogenesis
Inhibitors & Stimulators by Product Segments - Percentage
Breakdown of Dollar Sales for Angiogenesis Inhibitors &
Stimulators for Years 2005, 2010 and 2015 151
14. REST OF WORLD 152
A.Market Analysis 152
Angiogenesis Market - Making a Positive Move 152
Japanese Market 152
Quest for New Opportunities 152
B.Market Analytics 153
Table 30: Rest of World Recent Past, Current & Future
Analysis for Angiogenesis Inhibitors & Stimulators by
Product Segments-Angiogenesis Inhibitors and Angiogenesis
Stimulators Markets Independently Analyzed with Annual
Revenues in US$ Million for Years 2009 through 2015
(includes corresponding Graph/Chart) 153
Table 31: Rest of World Historic Review for Angiogenesis
Inhibitors & Stimulators by Product Segments- Angiogenesis
Inhibitors and Angiogenesis Stimulators Markets
Independently Analyzed with Annual Revenues in US$ Million
for Years 2003 through 2008 (includes corresponding
Graph/Chart) 154
Table 32: Rest of World 11-Year Perspective for Angiogenesis
Inhibitors & Stimulators by Product Segments - Percentage
Breakdown of Dollar Sales for Angiogenesis Inhibitors &
Stimulators for Years 2005, 2010 and 2015 154
COMPETITIVE LANDSCAPE
Total Companies Profiled: 72 (including Divisions/Subsidiaries - 84)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 50
Canada 2
Japan 3
Europe 21
France 2
Germany 5
The United Kingdom 5
Italy 3
Rest of Europe 6
Asia-Pacific (Excluding Japan) 8
------------------------------------------
To order this report:
: Global Angiongenesis Inhibitors and Stimulators Industry
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
